Ekso Bionics®’ EksoGT Exoskeleton Adopted in Singapore for Groundbreaking Clinical Study
May 06 2019 - 8:01AM
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced that the National University Health System (NUHS) in
Singapore has adopted three EksoGT exoskeletons for a
groundbreaking clinical study. NUHS is one of the first national
health systems in Asia to study how advanced exoskeleton technology
can improve mobility and rehabilitation outcomes, and the first to
study it across the entire continuum of care.
The Improving Mobility via Exoskeletons (iMOVE)
program, supported by Temasek Foundation and Trailblazer Foundation
Limited, will study patient outcomes and assess the viability and
potential for scaling-up the use of robotic exoskeletons across the
continuum of rehabilitation care from hospital to community.
The study will focus on patients suffering from stroke and spinal
cord injuries, especially for the elderly. The three EksoGT
devices will be used at multiple NUHS partner sites including
Alexandra Hospital, NTUC Health, St Luke’s Eldercare, St Luke’s
Hospital, and Stroke Support Station.
The iMOVE program was inaugurated today by Mr.
Chan Heng Kee, Permanent Secretary of Ministry of Health, together
with Professor John Wong Eu Li, Chief Executive of National
University Hospital System and Mr. Richard Magnus, Chairman of
Temasek Foundation.
“We are delighted to be part of a program that
will facilitate greater treatment accessibility in Singapore.
Globally 15 million people suffer from a stroke every year; Asia is
more than half the world’s population with a rapidly aging
population in many countries. With aging, mobility becomes a
big challenge. The core mission of Ekso is
to help people re-learn how to stand and walk after a stroke or
spinal cord injury. We want the EksoGT systems to be widely
accessible to people who never thought they could walk or stand up
again,” commented Ms. Lim Chwee Foon, President, Asia Pacific, Ekso
Bionics. “This will serve as a solid platform for our growth in
Asia.”
With Ekso Bionics’ recent expansion plan in Asia
Pacific, EksoGTs are now deployed in Singapore, Hong Kong, and
Australia. To date, EksoGT has helped patients take more than 100
million steps in over 260 rehabilitation institutions around the
world.
About EksoGTEksoGT is the first
exoskeleton cleared by the FDA for use with stroke and spinal cord
injuries from L5 to C7. In Europe, the CE-Mark cleared EksoGT
allows us to work with patients impacted by all neurological
conditions and lower limb weakness. The EksoGT with SmartAssist
software is the only exoskeleton available for rehabilitation
institutions that can provide adaptive amounts of power to either
side of a patient’s body, challenging the patient as they progress
through their continuum of care. The suit’s patented technology
provides the ability to mobilize patients earlier, more frequently,
and with a greater number of high intensity steps. To date, this
device has helped patients take 100 million steps in over 260
rehabilitation institutions around the world.
About Ekso Bionics® Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe. The company is
headquartered in the Bay Area and is listed on the Nasdaq Capital
Market under the symbol EKSO. For more information,
visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
including the iMOVE program and study results, (ii) estimates,
projections or other future statements regarding financial
performance, results and condition, capital expenditures, capital
structure or other financial items, including statements relating
to growth in Asia, and (iii) the assumptions underlying or relating
to any statement described in points (i) or (ii) above. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not be
realized because they are based upon the Company's current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contacts:
US:Glenn
Silver646-871-8485eksobionics@lazarpartners.com
APAC:Luiza LimFlame CommunicationsEmail:
luiza@flamecomms.comTel: (65) 6259 3193
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024